Holen Sie sich die Stockscreener-App
24.90
0.28%
-0.07
Handel nachbörslich:
25.39
0.49
+1.97%
Schlusskurs vom Vortag:
$24.97
Offen:
$24.97
24-Stunden-Volumen:
808.54K
Relative Volume:
0.63
Marktkapitalisierung:
$2.64B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-150.70M
KGV:
-16.06
EPS:
-1.55
Netto-Cashflow:
$-125.67M
1W Leistung:
+4.84%
1M Leistung:
+6.68%
6M Leistung:
+76.72%
1J Leistung:
-2.05%
1-Tages-Spanne:
$24.57
$25.41
1-Wochen-Bereich:
$22.78
$25.41
52-Wochen-Spanne:
$10.60
$30.48
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Vergleichen Sie EWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
24.90 | 2.64B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Eingeleitet | Goldman | Neutral |
| 2025-07-30 | Eingeleitet | Raymond James | Strong Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-30 | Eingeleitet | Guggenheim | Buy |
| 2025-04-02 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-22 | Eingeleitet | Stifel | Hold |
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
Is Edgewise Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Macro Moves & Growth Oriented Trade Recommendations - ulpravda.ru
Will Sure Ventures Plc (08F) stock extend growth storyRate Cut & Intraday High Probability Alerts - ulpravda.ru
Is Edgewise Therapeutics Inc. stock affected by interest rate hikesEarnings Performance Report & Free Verified High Yield Trade Plans - ulpravda.ru
How Edgewise Therapeutics Inc. stock compares to market leadersJuly 2025 Sentiment & Stock Portfolio Risk Control - ulpravda.ru
Will Edgewise Therapeutics Inc. stock remain a Wall Street favorite2025 Stock Rankings & Daily Growth Stock Investment Tips - ulpravda.ru
Why Edgewise Therapeutics Inc. stock is seen as undervaluedJuly 2025 Earnings & Accurate Intraday Trading Signals - ulpravda.ru
Why Edgewise Therapeutics Inc. stock could benefit from AI revolutionSwing Trade & Technical Pattern Based Signals - ulpravda.ru
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - MSN
A Look At Edgewise Therapeutics (EWTX) Valuation After Positive CIRRUS HCM Phase 2 Trial Update - Sahm
Edgewise Therapeutics CEO to outline 2026 goals at JPMorgan event - Traders Union
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Exploring a 61.93% Upside Potential in Biotech - DirectorsTalk Interviews
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - PR Newswire
Edgewise, a muscle disease biotech, to speak at J.P. Morgan conference - Stock Titan
Edgewise Therapeutics reports inducement grants as permitted by the Nasdaq Listing Rules - MarketScreener
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
H.C. Wainwright Maintains a Buy on Edgewise Therapeutics (EWTX), Sets a $42 PT - MSN
Edgewise Therapeutics Earnings Notes - Trefis
Aug Ideas: Can Edgewise Therapeutics Inc stock hit record highs againWeekly Investment Report & Momentum Based Trading Signals - moha.gov.vn
Edgewise Therapeutics rises 20.3% - MSN
Why Edgewise Therapeutics stock rocked the market today - MSN
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next - ts2.tech
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge - ts2.tech
Edgewise rises on mid-stage trial data for heart disease therapy - MSN
Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's What Happened - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Edgewise Therapeutics (EWTX) - The Globe and Mail
Valuation Update: Is Edgewise Therapeutics Inc stock a top pick in earnings seasonMarket Trend Report & Verified Entry Point Detection - moha.gov.vn
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits - The Globe and Mail
Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst (NASDAQ:EWTX) - Seeking Alpha
What drives Edgewise Therapeutics Inc stock priceHigh Dividend Yield Stocks & Free Trading Signals to Sharpen Your Edge - earlytimes.in
HC Wainwright says Edgewise data reinforces EDG-7500 potential differentiation - MSN
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Cut to Sell at Wall Street Zen - MarketBeat
Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.2%Here's Why - MarketBeat
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas - ts2.tech
Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study - MSN
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - BioSpace
Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout - Stocktwits
Edgewise Therapeutics (EWTX): Assessing Valuation After an 80% Three-Month Surge in the Share Price - Yahoo Finance
Edgewise Stock (+26%): Phase 2 HCM Safety Data Forces a Re-Rate - Trefis
Why Edgewise Therapeutics Stock Rocked the Market Today - Finviz
Why Edgewise Therapeutics Stock Rocked the Market Today - The Motley Fool
Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating - TipRanks
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):